Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jianmei He is active.

Publication


Featured researches published by Jianmei He.


PLOS ONE | 2015

Club Drugs and HIV/STD Infection: An Exploratory Analysis among Men Who Have Sex with Men in Changsha, China

Xi Chen; Li Xl; Jun Zheng; Junshi Zhao; Jianmei He; Guoqiang Zhang; Xuemin Tang

Objective To evaluate current club drug use and its potential association with the transmission of HIV/STD among Changsha men who have sex with men (MSM). Method A cross-sectional survey was conducted by using self-administered questionnaires including information regarding socio-demographics, club drug use, high-risk behaviors, and HIV/STD infections. Multiple methods including venue-based, peer referral using “snowball” techniques, and internet advertisements were used to recruit study participants. Results Of the 826 participants, 177 (21.4%) reported that they had used club drugs at some time before or during sex in the past six months. MSM with young age, low education level, and seeking partners through the internet or bars were the main population who used drugs. Poppers were the most common drug used among Changsha MSM. The prevalence of HIV, syphilis, and herpes simplex virus-2 were higher among drug users. There were no significant differences in unprotected sexual intercourse and condom use between drug users and non-users. Compared with non-users, risk behaviors such as group sex, multiple sex partners, and sex with foreigners were more frequent among drug users. Conclusion Club drug use is common among Changsha MSM, and is related to unsafe sex activities and HIV/STD infection. It is necessary to build novel targeted HIV prevention strategies to monitor and reduce club drug use among MSM.


PLOS ONE | 2013

Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment.

Hui Xing; Xia Wang; Lingjie Liao; Yanling Ma; Bin Su; Jihua Fu; Jianmei He; Lin Chen; Xiaohong Pan; Yonghui Dong; Wei Liu; Jenny H. Hsi; Liting Yang; Yuhua Ruan; Yiming Shao

Background A critical indicator of the future success of highly active antiretroviral therapy (HAART) is the incidence of HIV drug resistance, which has not been studied in China on the national scale. Methods HIV drug resistance baseline survey was conducted in the eight provinces with the largest numbers of patients on HAART in 2009, and a prospective cohort study with 12-month follow-up was completed in 2010. Patients completed an interviewer-administrated questionnaire and provided blood for CD4+ T-lymphocyte count (CD4 count), HIV viral load (VL), and HIV drug resistance genotyping. Factors associated with incidence of HIVDR were identified by Cox regression analysis. Results The overall prevalence of HIV RNA ≥1000 copies/ml and HIVDR at baseline was 12.4% and 5.6%, respectively. Incidence of HIVDR in the one year follow-up was 3.5 per 100 person years. Independently associated factors were started treatment with a didanosine-based regimen, received care at township hospital or village clinic, low baseline CD4 counts, and high baseline VL. Conclusions The incidence of HIVDR in China was higher than that of some developed countries. China urgently needs to provide comprehensive education and training to doctors at village clinics and township hospitals to improve quality community-based care and treatment.


PLOS ONE | 2014

Prevalence of WHO Transmitted Drug Resistance Mutations by Deep Sequencing in Antiretroviral-Naïve Subjects in Hunan Province, China

Zou Xiaobai; Chen Xi; Hongping Tian; Ann Bartley Williams; Honghong Wang; Jianmei He; Jun Zhen; Jennifer Chiarella; Lisebeth A. Blake; Gregory S. Turenchalk; Michael J. Kozal

Background There are few data on the prevalence of WHO transmitted drug resistance mutations (TDRs) that could affect treatment responses to first line antiretroviral therapy (ART) in Hunan Province, China. Objective Determine the prevalence of WHO NRTI/NNRTI/PI TDRs in ART-naïve subjects in Hunan Province by deep sequencing. Methods ART-naïve subjects diagnosed in Hunan between 2010–2011 were evaluated by deep sequencing for low-frequency HIV variants possessing WHO TDRs to 1% levels. Mutations were scored using the HIVdb.stanford.edu algorithm to infer drug susceptibility. Results Deep sequencing was performed on samples from 90 ART-naïve subjects; 83.3% were AE subtype. All subjects had advanced disease (average CD4 count 134 cells/mm3). Overall 25.6%(23/90) of subjects had HIV with major WHO NRTI/NNRTI TDRs by deep sequencing at a variant frequency level ≥1%; 16.7%(15/90) had NRTI TDR and 12.2%(11/90) had a major NNRTI TDR. The majority of NRTI/NNRTI mutations were identified at variant levels <5%. Mutations were analyzed by HIVdb.stanford.edu and 7.8% of subjects had variants with high-level nevirapine resistance; 4.4% had high-level NRTI resistance. Deep sequencing identified 24(27.6%) subjects with variants possessing either a PI TDR or hivdb.stanford.edu PI mutation (algorithm value≥15). 17(19.5%) had PI TDRs at levels >1%. Conclusions ART-naïve subjects from Hunan Province China infected predominantly with subtype AE frequently possessed HIV variants with WHO NRTI/NNRTI TDRs by deep sequencing that would affect the first line ART used in the region. Specific mutations conferring nevirapine high-level resistance were identified in 7.8% of subjects. The majority of TDRs detected were at variant levels <5% likely due to subjects having advanced chronic disease at the time of testing. PI TDRs were identified frequently, but were found in isolation and at low variant frequency. As PI/r use is infrequent in Hunan, the existence of PI mutations likely represent AE subtype natural polymorphism at low variant level frequency.


PLOS ONE | 2014

Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012.

Jing Wang; Cui He; Jenny H. Hsi; Xiaoqin Xu; Yong Liu; Jianmei He; Hua Ling; Ping Ding; Yi Tong; Xiaobai Zou; Quanhua Zhou; Lingjie Liao; Xia Wang; Yuhua Ruan; Yiming Shao; Hui Xing

Objective To determine the prevalence of virological failure and HIV drug resistance among Chinese patients one year after initiating lamivudine-based first-line antiretroviral treatment. Methods A prospective cohort study with follow-up at 12 months was conducted in four urban sentinel sites in China. Antiretroviral naive patients ≥18 years old were recruited. Blood samples were collected for testing CD4 cell count, viral load, and (for samples with HIV-1 RNA ≥1000 copies/ml) genotyping of drug resistance. Results A total of 513 patients were enrolled in this cohort, of whom 448 (87.3%) were retained at 12 months. The median final CD4 cell count was 313 cells/mm3, which increased from 192 cells/mm3 at baseline (P<0.0001). Of the 448 remaining subjects, 394 (87.9%) had successful virological suppression (HIV RNA <1000 copies/ml). Among 54 samples with viral load ≥1000 copies/ml, 40 were successfully genotyped, and 11 were found with detectable HIV drug resistance mutations. Of these, the proportions of drug resistance to NNRTIs, NRTIs and PIs were 100%, 81.8% and 0%, respectively. Injecting drug use (AOR = 0.40, 95% CI: 0.19,0.84; P = 0.0154), CD4 count at baseline ≥350 cells/mm3 (AOR = 0.32, 95% CI: 0.14,0.72; P = 0.0056), and missed doses in the past month (AOR = 0.30, 95% CI: 0.15,0.60; P = 0.0006) were significantly negatively associated with HIV RNA <1000 copies/ml. Conclusions Our study demonstrates effective virological and immunological outcomes at 12 months among these who initiated first-line ART treatment. However, patients infected through drug injection, who missed doses, or with higher CD4 count at baseline are at increased risk for poor virological response.


PLOS ONE | 2016

HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China.

Xi Chen; Xiaobai Zou; Jianmei He; Jun Zheng; Jennifer Chiarella; Michael J. Kozal

Objective Determine HIV drug resistance mutations (DRMs) prevalence at low and high levels in ART-experienced patients experiencing virologic failure (VF). Methods 29 subjects from 18 counties in Hunan Province that experienced VF were evaluated for the prevalence of DRMs (Stanford DRMs with an algorithm value ≥15, include low-, intermediate and high-level resistance) by both Sanger sequencing (SS) and deep sequencing (DS) to 1% frequency levels. Results DS was performed on samples from 29 ART-experienced subjects; the median viral load 4.95×104 c/ml; 82.76% subtype CRF01_AE. 58 DRMs were detected by DS. 18 DRMs were detected by SS. Of the 58 mutations detected by DS, 40 were at levels <20% frequency (26 NNRTI, 12 NRTI and 2 PI) and the majority of these 95.00% (38/40) were not detected by standard genotyping. Of these 40 low-level DRMs, 16 (40%) were detected at frequency levels of 1–4% and 24 (60%) at levels of 5–19%. SS detected 15 of 17 (88.24%) DRMs at levels ≥ 20% that were detected by DS. The only variable associated with the detection of DRMs by DS was ART adherence (missed doses in the prior 7 days); all patients that reported missing a dose in the last 7 days had DRMs detected by DS. Conclusions DS of VF samples from treatment experienced subjects infected with primarily AE subtype frequently identified Stanford HIVdb NRTI and NNRTI resistance mutations with an algorithm value 15. Low frequency level resistant variants detected by DS were frequently missed by standard genotyping in VF specimens from antiretroviral-experienced subjects.


Scientific Reports | 2017

Phylodynamics of major CRF01_AE epidemic clusters circulating in mainland of China

Xiaolin Wang; Xiang He; Ping Zhong; Yongjian Liu; Tao Gui; Dijing Jia; Hanping Li; Jianjun Wu; Jin Yan; Dianmin Kang; Yang Han; Taisheng Li; Rongge Yang; Xiaoxu Han; Lin Chen; Jin Zhao; Hui Xing; Shu Liang; Jianmei He; Yansheng Yan; Yile Xue; Jiafeng Zhang; Xun Zhuang; Shujia Liang; Zuoyi Bao; Tianyi Li; Daomin Zhuang; Siyang Liu; Jingwan Han; Lei Jia

As the most dominant HIV-1 strain in China, CRF01_AE needs to have its evolutionary and demographic history documented. In this study, we provide phylogenetic analysis of all CRF01_AE pol sequences identified in mainland China. CRF01_AE sequences were collected from the Los Alamos HIV Sequence Database and the local Chinese provincial centers of disease control and prevention. Phylogenetic trees were constructed to identify major epidemic clusters. Bayesian coalescent-based method was used to reconstruct the time scale and demographic history. There were 2965 CRF01_AE sequences from 24 Chinese provinces that were collected, and 5 major epidemic clusters containing 85% of the total CRF01_AE sequences were identified. Every cluster contains sequences from more than 10 provinces with 1 or 2 dominant transmission routes. One cluster arose in the 1990s and 4 clusters arose in the 2000s. Cluster I is in the decline stage, while the other clusters are in the stable stage. Obvious lineage can be observed among sequences from the same transmission route but not the same area. Two large clusters in high-level prevalence were found in MSM (Men who have sex with men), which highlighted that more emphasis should be placed on MSM for HIV control in mainland China.


Archives of Virology | 2013

Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in central China

Xi Chen; Jianmei He; Li-Sha Ding; Guoqiang Zhang; Xiaobai Zou; Jun Zheng


AIDS Research and Human Retroviruses | 2012

Short Communication: Emerging Transmitted HIV Type 1 Drug Resistance Mutations Among Patients Prior to Start of First-Line Antiretroviral Therapy in Middle and Low Prevalence Sites in China

Xia Wang; Cui He; Hui Xing; Lingjie Liao; Xiaoqin Xu; Jianmei He; Yong Liu; Hua Ling; Shu Liang; Jenny H. Hsi; Yuhua Ruan; Yiming Shao


Chinese journal of epidemiology | 2009

[Genetic characteristics of HIV-1 CRF01_AE strains in four provinces, southern China].

Chun-Lin Cheng; Yi Feng; Xiang He; Peng Lin; Shujia Liang; Zhi-Qiang Yi; Jianmei He; Yuanyuan Hu; Hui Xing; Yan Fan; Shi-Liang Wu; Yiming Shao


Sexually Transmitted Diseases | 2012

Older HIV-positive adults in Xiangxi China: infection modes and associated risk factors.

Xi Chen; Li Xl; Biyun Qin; Jun Zheng; Jianmei He; Lu Wang; Ning Wang; Ann Hsu; Kaveh Khoshnood

Collaboration


Dive into the Jianmei He's collaboration.

Top Co-Authors

Avatar

Xi Chen

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Hui Xing

Chinese Center for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jun Zheng

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Yiming Shao

Chinese Center for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Lingjie Liao

Chinese Center for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Xia Wang

Chinese Center for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Yuhua Ruan

Chinese Center for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lin Chen

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge